For the quarter ending 2026-03-31, ANIK made $29,612K in revenue. -$5,407K in net income. Net profit margin of -18.26%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | 29,612 | 28,766* | 27,817 | 28,219 |
| Cost of revenue | 10,615 | 9,879* | 12,233 | 13,856 |
| Gross profit | 18,997 | 18,887* | 15,584 | 14,363 |
| Research & development | 6,713 | 5,882* | 6,946 | 6,313 |
| Selling, general & administrative | 17,772 | 12,937* | 11,871 | 12,230 |
| Total operating expenses | 24,485 | 18,818* | 18,817 | 18,543 |
| Gain from operations | -5,488 | 69* | -3,233 | -4,180 |
| Interest and other income, net | 667 | -72* | 997 | 214 |
| Loss before income taxes | -4,821 | -4* | -2,236 | -3,966 |
| Provision for income taxes | 235 | -1,758* | 939 | 681 |
| Gain from continuing operations | -5,056 | 1,754* | -3,175 | -4,647 |
| Loss from discontinued operations, net of tax | 0 | -3,185* | 846 | 677 |
| Net loss | -5,056 | -1,431* | -2,329 | -3,970 |
| Foreign currency translation adjustment | -351 | 78* | -184 | 1,348 |
| Comprehensive loss | -5,407 | -1,353 | -2,513 | -2,622 |
| Basic EPS | -0.37 | -0.095 | -0.16 | -0.28 |
| Diluted EPS | -0.37 | -0.096 | -0.16 | -0.28 |
| Basic Average Shares | 13,531,000 | 14,234,000 | 14,419,000 | 14,364,000 |
| Diluted Average Shares | 13,531,000 | 14,081,000 | 14,419,000 | 14,517,000 |
Anika Therapeutics, Inc. (ANIK)
Anika Therapeutics, Inc. (ANIK)